Effect of Rubus Occidentalis Extract on Plasma Glucose Levels in Subject With Prediabetes
Primary Purpose
Prediabetes (Impaired Fasting Glucose and/or Impaired Glucose Tolerance)
Status
Completed
Phase
Phase 4
Locations
Study Type
Interventional
Intervention
Rubus occidentalis extract
Sponsored by
About this trial
This is an interventional treatment trial for Prediabetes (Impaired Fasting Glucose and/or Impaired Glucose Tolerance)
Eligibility Criteria
Inclusion Criteria:
- 19 years of age or older
- prediabetes (fasting plasma glucose 100-125mg/dl, and/or post 75g OGTT plasma glucose 140-199mg/dl)
Exclusion Criteria:
- pregnant women
- taking anti-hyperglycemic agents within 3 months at the time of enrollment
- history of heart failure, myocardial infarction, cerebral infarction
- uncontrolled hypertension (systolic BP > 160mmHg, or diastolic BP > 100mmHg)
- serum triglyceride level > 500mg/dl
- kidney dysfunction (serum Creatinine > 30% of upper normal limits)
- hepatic dysfunction (AST, ALT > 3 times of upper normal limits)
- taking systemic glucocorticoids within 1 month
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Placebo Comparator
Active Comparator
Active Comparator
Arm Label
control
Rubus occidentalis extract 900mg
Rubus occidentalis extract 1800mg
Arm Description
taking Rubus occidentalis extract 900mg/day for 12weeks
taking Rubus occidentalis extract 1800mg/day for 12weeks
Outcomes
Primary Outcome Measures
serum glucose (fasting and post 75g oral glucose tolerance test)
Secondary Outcome Measures
serum insulin
Full Information
NCT ID
NCT01964703
First Posted
October 14, 2013
Last Updated
October 14, 2013
Sponsor
Korea University Anam Hospital
1. Study Identification
Unique Protocol Identification Number
NCT01964703
Brief Title
Effect of Rubus Occidentalis Extract on Plasma Glucose Levels in Subject With Prediabetes
Official Title
Effect of Rubus Occidentalis Extract on Plasma Glucose Levels in Subject With Prediabetes; A Proof-of-concept, Randomized, Double-blind, Parallel-group Placebo-controlled Study
Study Type
Interventional
2. Study Status
Record Verification Date
October 2013
Overall Recruitment Status
Completed
Study Start Date
April 2013 (undefined)
Primary Completion Date
October 2013 (Actual)
Study Completion Date
undefined (undefined)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Korea University Anam Hospital
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The purpose of this study is to determine whether Rubus occidentalis extract could improve fasting or postprandial serum glucose levels, and related metabolic markers among patients with prediabetes (impaired fasting glucose and/or impaired glucose tolerance).
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Prediabetes (Impaired Fasting Glucose and/or Impaired Glucose Tolerance)
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
29 (Actual)
8. Arms, Groups, and Interventions
Arm Title
control
Arm Type
Placebo Comparator
Arm Title
Rubus occidentalis extract 900mg
Arm Type
Active Comparator
Arm Description
taking Rubus occidentalis extract 900mg/day for 12weeks
Arm Title
Rubus occidentalis extract 1800mg
Arm Type
Active Comparator
Arm Description
taking Rubus occidentalis extract 1800mg/day for 12weeks
Intervention Type
Drug
Intervention Name(s)
Rubus occidentalis extract
Primary Outcome Measure Information:
Title
serum glucose (fasting and post 75g oral glucose tolerance test)
Time Frame
12 weeks
Secondary Outcome Measure Information:
Title
serum insulin
Time Frame
12 weeks
Other Pre-specified Outcome Measures:
Title
HOMA IR, QUICKI, HOMA beta, lipid profile, inflammatory markers
Time Frame
12 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
19 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
19 years of age or older
prediabetes (fasting plasma glucose 100-125mg/dl, and/or post 75g OGTT plasma glucose 140-199mg/dl)
Exclusion Criteria:
pregnant women
taking anti-hyperglycemic agents within 3 months at the time of enrollment
history of heart failure, myocardial infarction, cerebral infarction
uncontrolled hypertension (systolic BP > 160mmHg, or diastolic BP > 100mmHg)
serum triglyceride level > 500mg/dl
kidney dysfunction (serum Creatinine > 30% of upper normal limits)
hepatic dysfunction (AST, ALT > 3 times of upper normal limits)
taking systemic glucocorticoids within 1 month
12. IPD Sharing Statement
Citations:
PubMed Identifier
27279471
Citation
An JH, Kim DL, Lee TB, Kim KJ, Kim SH, Kim NH, Kim HY, Choi DS, Kim SG. Effect of Rubus Occidentalis Extract on Metabolic Parameters in Subjects with Prediabetes: A Proof-of-concept, Randomized, Double-blind, Placebo-controlled Clinical Trial. Phytother Res. 2016 Oct;30(10):1634-1640. doi: 10.1002/ptr.5664. Epub 2016 Jun 9.
Results Reference
derived
Learn more about this trial
Effect of Rubus Occidentalis Extract on Plasma Glucose Levels in Subject With Prediabetes
We'll reach out to this number within 24 hrs